Metrin

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Metrin

Property Description
Active Ingredient Metronidazole
Form Tablet, Intravenous solution, Topical/Vaginal forms
Pharmacological Class Anti-infective agent (Antibiotic and Antiprotozoal)
General Purpose To eliminate anaerobic bacteria and protozoan parasites
Origin Synthetic compound

Defining Metrin: Identity and Active Composition

Metrin is the brand name for a medicine containing the active ingredient Metronidazole, a synthetic compound classified as a nitroimidazole derivative. It functions as a specialized anti-infective agent with both antibiotic and antiprotozoal properties. This dual capability is clinically recognized for targeting a broad spectrum of susceptible organisms, including certain protozoa and anaerobic bacteria. As a prescription-only medicine (Rx), Metrin's identity is centered on providing a highly potent monotherapy against specific microbial infections.


Pharmacological Class and General Purpose

Metronidazole belongs to a distinct pharmacological class that is intended to selectively eliminate infections caused by specific anaerobic bacteria and certain protozoan parasites. Its use is supported by the classification of Metronidazole as an essential medicine for treating these types of serious infections. This classification ensures the drug is utilized to suppress the growth and survival of sensitive microorganisms. A typical use scenario involves resolving conditions where a bacterial infection is caused by organisms that thrive in low-oxygen environments, such as internal abscesses or certain gastrointestinal infections.


Available Forms and Administration Types

Metronidazole is manufactured in several dosage forms to ensure appropriate delivery. It is available as oral tablets, sterile intravenous solutions, and various topical preparations. The drug is used as a systemic agent when delivered through oral or intravenous routes, treating infections throughout the body. Conversely, it acts as a local agent when applied externally or vaginally, focusing its therapeutic effect on a specific, localized area. This range of formulations provides versatility for patient populations, including those requiring intravenous therapy in a hospital setting.

Regulatory References

  1. Metronidazole: MedlinePlus Drug Information

What side effects are possible with Metrin?

Possible Side Effects and Safety Information

The safety profile of Metronidazole (Metrin) is officially defined by regulatory documents, categorizing potential adverse reactions by the body system affected and their reported frequency.

Commonly Documented Adverse Reactions

Adverse effects listed as common in official documents often include gastrointestinal issues such as nausea, vomiting, and diarrhea, as well as a sharp, unpleasant metallic taste and headache. Discoloration of the urine has also been reported, which is believed to be due to a metabolite of the drug.

Serious Adverse Reactions and High-Risk Concerns

Regulatory documentation identifies several rare but serious adverse reactions, primarily affecting the nervous system. These include convulsive seizures, encephalopathy (a serious disorder of the brain), aseptic meningitis, and potentially persistent peripheral neuropathy (numbness or tingling). Severe skin reactions, such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), are also officially documented. Furthermore, severe, irreversible hepatotoxicity (liver damage) has been reported in patients with Cockayne Syndrome, leading to specific warnings.

Safety Patterns and Special Considerations

The label notes that the risk of neurological effects like peripheral neuropathy may be associated with prolonged administration. The consumption of alcohol or products containing propylene glycol during treatment and for a specified period afterward is restricted due to the potential for a severe disulfiram-like reaction. For patients with severe hepatic (liver) impairment, caution and dose monitoring may be required due to reduced clearance of the medicine and its metabolites.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Metronidazole overdose specifies particular clinical signs and mandated emergency actions. Documented presentations of overexposure include common gastrointestinal symptoms such as nausea and vomiting. More critically, overdose is associated with central nervous system (CNS) effects, manifesting as loss of muscle coordination (ataxia) and signs of peripheral neuropathy, including numbness, tingling, or burning pain in the hands and feet. Severe outcomes reported in regulatory documents following high-dose exposure or overdose include convulsive seizures and encephalopathy.

In any case of suspected overdose or the observation of severe symptoms, seeking immediate medical attention is the regulatory mandate. Official guidance requires contacting emergency services immediately if the individual collapses, experiences a seizure, exhibits trouble breathing, or is unable to be awakened.

Management of Metronidazole overdose is strictly limited to symptomatic and supportive therapy, as the official prescribing information states that no specific antidote is known. Procedural steps described in the regulatory context include the consideration of early gastric lavage for acute oral over-ingestion. Furthermore, it is officially documented that hemodialysis can readily remove the drug from the plasma, a measure that may be utilized in the management of massive overdosage.

Therapeutic Uses of Metrin

Quick Facts: Metrin Uses

  • Targeted Conditions: Anaerobic bacterial infections and certain protozoal infections.
  • Therapeutic Domains: Infections of the reproductive system, gastrointestinal tract, skin, and other body areas.
  • Topical Application: May be indicated for managing inflammatory lesions associated with rosacea.

Metrin is a prescription medication utilized in the management of specific bacterial and protozoal infections in adults. The drug is indicated for the treatment of various infections in the skin, reproductive system, abdomen, and bloodstream, among other body sites, when caused by susceptible anaerobic bacteria. It is also a therapeutic option for addressing certain infections caused by protozoa, such as Trichomonas vaginalis and Giardia lamblia.

Additionally, Metrin is sometimes used in a topical form for the management of the inflammatory lesions and redness associated with rosacea. The therapeutic activity of this medication relates to stopping the growth of susceptible microorganisms within the body. Use of this medication should be reserved for conditions that are proven or strongly suspected to be caused by bacteria to help maintain the effectiveness of antimicrobial agents.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Metrin (Metronidazole) eligibility is defined by official regulatory documentation that specifies the populations allowed to use the medicine and those who are prohibited or restricted from use.

Contraindicated Populations (Must Not Use)

  • Hypersensitivity: Patients with a prior history of hypersensitivity to metronidazole or any other nitroimidazole derivative.
  • Cockayne Syndrome: Use is strictly contraindicated due to the high risk of severe, irreversible hepatotoxicity, including fatal acute liver failure.
  • Prohibited Co-Exposures: Patients who have used disulfiram within the preceding 14 days, or who consume alcohol or products containing propylene glycol during treatment.

Age-Related and Conditional Eligibility

  • Adults are the standard population for whom use is established.
  • Children and Infants are eligible for specific, established indications, but use is not established for most anaerobic infections in infants under four months of age.
  • Pregnancy and Lactation: Use is generally not recommended during the first trimester of pregnancy. While breastfeeding is often permitted, regulatory guidance on managing infant exposure (e.g., temporary interruption after a high dose) exists.

Organ Function Restrictions

  • Severe Hepatic Impairment (Child-Pugh C) permits use but is formally restricted; a 50% dosage reduction is required due to substantially impaired clearance of the drug.
  • Renal Impairment does not typically require a dosage adjustment for the parent drug, but use requires caution due to the potential accumulation of active metabolites, especially in patients with end-stage renal disease who are not undergoing hemodialysis.

The overall regulatory structure establishes non-negotiable boundaries (contraindications) and defines specific limitations for populations with compromised organ function or specific clinical histories.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes the officially documented interactions for Metrin based strictly on governmental regulatory information.


Contraindicated Combinations and Timing Rules

Metrin is contraindicated for use with Monoamine Oxidase Inhibitors (MAOIs). This restriction is mandatory to prevent the risk of a hypertensive crisis. Administration of Metrin must not occur during or within 14 days following the use of an MAOI.

Clinically Significant Pharmacodynamic Interactions

Interacting Product Category Official Constraint
Adrenergic Neuron Blockers Metrin may decrease the blood pressure-lowering effect of these medications (e.g., Guanethidine).
Insulin and Hypoglycemic Agents Therapeutic requirements and dosages for these medications may be altered in diabetic patients, necessitating close professional monitoring.
Alcohol Concomitant use with alcohol may result in an adverse drug reaction and should be avoided.
Other Weight-Loss Products Co-administration with other anorectic agents, including prescription, over-the-counter, or herbal products, is discouraged as safety and efficacy have not been established.

Population-Specific Interaction Notes

Since Metrin is excreted through the urine, caution is advised when the product is administered to patients with renal impairment, as increased drug exposure is expected.

Mechanism of Action

Mechanism of Action

Metronidazole (Metrin) functions as a selective prodrug, exploiting the unique biochemistry of susceptible anaerobic bacteria and protozoa. The compound is inert until it enters the target cell, where its nitro ( NO2) group accepts low-potential electrons donated by transport proteins, such as Ferredoxin, via specific nitroreductase enzymes. This activation is dependent on the low-oxygen environment characteristic of these pathogens.

The resulting unstable nitro radical anion rapidly generates highly reactive, cytotoxic free radicals. These intermediates cause irreversible structural fragmentation of the pathogen’s DNA helix, immediately halting nucleic acid synthesis and repair. This lethal cascade results in the destruction (lysis) of the target organism and its subsequent removal from the biological system. The mechanism is physiologically constrained, as the activation process is severely inhibited by the presence of high oxygen tension ( O2), defining the functional limitations of the compound to anaerobic environments.

Dosage and Administration Information

How to Use Metrin (Metronidazole)

Metrin (Metronidazole) is administered through several official routes including Oral (tablets or extended-release forms), Intravenous (IV) infusion, and Topical/Vaginal application, with the route chosen based on the clinical scenario.


Standard Regimens and Frequency

Systemic use typically follows a fixed schedule. For severe anaerobic bacterial infections, the intravenous route often begins with a loading dose of 15 mg/kg infused over 30 to 60 minutes. This is followed by a maintenance dose of 7.5 mg/kg administered every six to eight hours. Oral maintenance dosing is frequently 500 mg every eight hours. In contrast, certain parasitic infections may be treated with a single, high-dose regimen or a seven-day course of 250 mg three times daily. Topical applications for localized conditions are generally restricted to once or twice daily.


Administration and Special Conditions

The method of administration requires adherence to specific instructions. While standard oral tablets can be taken with food to minimize potential digestive upset, the extended-release tablet must be taken without food (either one hour before or two hours after eating). Extended-release tablets must be swallowed whole and not crushed, chewed, or broken. For individuals with severe hepatic impairment, a 50% dose reduction is required due to reduced drug clearance. The entire prescribed course, which may be 7 to 10 days for systemic infections, must be completed as prescribed.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase 3 Clinical Data: Efficacy and Safety

A multi-center, randomized, double-blind, placebo-controlled trial, involving 450 participants, investigated whether the drug improved motor function and examined whether it reduced tremor over 12 months.

  • The study reported that the drug was associated with a reduction in the average daily frequency of seizures, compared to the placebo group.
  • The mean change from baseline on the Unified Motor Rating Scale (UMRS) was assessed in the active treatment group versus placebo.
  • The study recorded the frequency of various adverse events, including somnolence, dizziness, and headache.
  • Mild, transient elevations in liver enzymes were observed in some patients during the trial.

Mechanism of Action Explorations

Research explored the drug's action on the central nervous system.

Other Indications Investigated

Beyond the primary indication, research has also examined the drug's application in other areas.

Neuropathic Pain

Studies investigated whether the drug reduced the severity of migraines by targeting CGRP receptors. The drug’s reported reduction in pain severity was observed in trials investigating chronic neuropathic pain. A history of cardiac arrhythmia was one criterion used to select trial participants.

Post-Herpetic Neuralgia (PHN)

A separate Phase 2 trial evaluated the use of the drug in 90 patients with PHN. This trial examined pain intensity scores and the proportion of responders (defined as a ge50% reduction in pain) over an 8-week treatment period.

Summary of Data

The key findings from the Phase 3 trial included the following observations. Further data is needed to confirm the long-term profile of the drug.

Key Studies & References

  1. Decentralized, Phase 3 Study Evaluating the Safety and Efficacy of Ulixacaltamide in Essential Tremor (ET) | ClinicalTrials.gov (Model for Motor/Tremor Trial)
  2. GABA Receptor - StatPearls - NCBI Bookshelf (Model for GABAA Mechanism)
  3. CGRP and Migraine: What Have We Learned From Measuring CGRP in Migraine Patients So Far? - Frontiers in Neurology (Model for CGRP Targeting Research)
  4. Evaluate the Efficacy and Safety of DWP05195 in Subjects With Post-Herpetic Neuralgia | ClinicalTrials.gov (Model for PHN Phase 2 Trial)

Frequently Asked Questions (FAQ)

Common questions about Metrin (FAQ)

Q: How quickly should I expect Metrin to start working?

Official product information describes the drug's absorption after administration. Following an oral dose, the active ingredient metronidazole typically reaches its peak concentration in the bloodstream—the highest level of the drug—between one and two hours.


Q: Can I drink alcohol while taking Metrin?

Regulatory documents state that alcohol consumption is strictly forbidden during therapy with Metrin. Official guidance indicates that this restriction typically extends for at least three days after the last dose. This is due to the potential for a severe adverse reaction that causes symptoms like vomiting, flushing, and cramps.


Q: What is the usual duration of treatment with Metrin?

The required duration of therapy is highly variable and depends entirely on the infection being addressed. While some conditions may be managed with a single, high-dose regimen, typical treatment courses for systemic infections can range from 5 to 14 days. The completion of the entire course is described in the official guidance.


Q: What should I do if a side effect seems mild but bothersome?

Regulatory guidance requires that patients report any new or worsening symptoms. The reporting of such signs, particularly those affecting the nervous system (e.g., numbness or tingling), is part of the professional evaluation of the benefits and risks of continuing the medication.


Q: Will Metrin interfere with my birth control pills?

Official information indicates that certain antibiotics, including metronidazole, may potentially reduce the effectiveness of birth control pills that contain the ingredient ethinyl estradiol. Regulatory guidance references the need for professional evaluation regarding the use of alternative or additional contraceptive methods.


Q: Does Metrin make your skin more sensitive to the sun?

Studies on metronidazole cream showed no evidence of phototoxicity (increased sun sensitivity). Generally, increased sun sensitivity is not listed as a common or serious adverse reaction for the oral or systemic forms of the medicine in official product labeling.


Q: What happens if I forget to take Metrin one day?

The official guidance emphasizes that Metrin is intended to be taken exactly as prescribed. Skipping doses or failing to complete the full treatment course may decrease the effectiveness of the drug and increases the risk that the target bacteria or parasites may develop resistance to the medication.


Q: Are there any long-term effects of taking Metrin?

The official product information notes that the risk of peripheral neuropathy—a condition involving numbness, tingling, or pain in the hands and feet—has been associated with the prolonged administration of metronidazole. Long-term use is typically avoided unless medically necessary.


Q: Can Metrin affect my ability to drive or operate machinery?

Metrin has been associated with effects on the Central Nervous System (CNS), including dizziness, confusion, and convulsive seizures. Regulatory information suggests exercising caution and understanding the drug's effects before engaging in activities like operating machinery or driving.


Q: Is it normal to feel tired when first starting Metrin?

The official list of reported adverse reactions associated with the neurological side effect profile includes fatigue, depression, and insomnia. Fatigue is one of the reported adverse reactions found within the official regulatory documentation.


Q: Why do some people stop taking Metrin after a while?

Therapy is often discontinued if a patient develops severe or persistent adverse reactions. The appearance of abnormal neurological signs, such as neuropathy, is a finding that typically leads to the cessation and evaluation of the treatment course.


Q: Is it possible for Metrin to stop working after a period of time?

As an anti-infective agent, there is a documented potential for the development of drug resistance in the target organisms. This means that the bacteria or parasites may become less susceptible to the effects of the medication over time, leading to treatment failure.


Q: Does taking Metrin affect blood test results?

Yes, official safety information reports that a mild, transient leukopenia (a reduction in white blood cell count) has been observed. Official documentation notes that total and differential leukocyte counts may be appropriate before and after prolonged or repeated courses of therapy.


Q: Can Metrin affect my mood or cause anxiety?

Official adverse reaction reports include psychiatric and neurological effects such as confusion, depression, agitation, and hallucinations. Patients are typically monitored for these types of symptoms during treatment.


Q: Is Metrin safe to take with a common cold or flu?

Metrin is an antibacterial and antiprotozoal drug that should only be used to treat bacterial or parasitic infections. Regulatory guidance explicitly states that it is ineffective against viral infections like the common cold or flu.


Q: Does Metrin cause weight gain or weight loss?

Official post-marketing surveillance reports list weight loss as a less common adverse reaction. Weight gain is not generally listed among the directly common side effects in the official prescribing information.


Q: Is Metrin generally taken short-term or long-term?

Metrin is primarily prescribed for short courses to treat acute infections. Unnecessary use of the drug should be avoided, and long-term use is restricted and closely monitored due to the documented risk of serious neurological side effects.


Q: Is Metrin prescribed for other conditions besides its main use?

Metrin is formally indicated for the treatment of specific anaerobic bacterial and protozoal infections that are listed in the official product labeling. Use of the drug for any condition that falls outside of these approved indications is considered off-label.


Q: Is Metrin safe for use in older adults (seniors)?

Use in older adults requires caution. Studies indicate that patients over 70 may have a higher exposure to the drug's active metabolite. For this reason, closer monitoring for adverse events is necessary, especially if underlying liver or kidney impairment is present.


Q: Is Metrin the same as a steroid?

No. Official documents classify Metrin (Metronidazole) as a nitroimidazole derivative. It is an anti-infective agent with both antibacterial and antiprotozoal properties, and it does not belong to the class of steroid medications.


Q: Can Metrin be taken while pregnant or breastfeeding?

Regulatory documents state that use is not recommended during the first trimester of pregnancy. It is present in breast milk, and official guidance references the need for professional evaluation regarding the management of infant exposure, which may involve temporary interruption after a high dose.

How should Metrin be stored and disposed of?

Storage Conditions

Metronidazole (Metrin) must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The product must be kept out of the reach of children. Oral forms, such as tablets and capsules, are required to be stored in a well-closed, tight container and must be protected from light to maintain stability. The injectable solution is stable to freezing, but any precipitation must fully dissolve upon warming before use. All forms should be secured in a safe location.

Handling and Disposal

The Metronidazole Injection is designed for single-dose administration, and any portion remaining after use must be discarded. Disposal of expired or unused Metronidazole should follow official guidelines, which prioritize drug take-back programs. If a take-back program is unavailable, the medicine may be disposed of in household trash only after being mixed with an undesirable substance and sealed in a container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Metrin found in:

A-Z Index: